PPADS (tetrasodium)

CAT: 0804-HY-101044-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-101044-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca2+ exchanger in guinea pig airway smooth muscle[1][2].
CAS Number
[192575-19-2]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Na+/Ca2+ Exchanger; P2X Receptor
Related Pathways
Membrane Transporter/Ion Channel
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Purity
99.9
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=C(/N=N/C2=NC(C)=C(O)C(C=O)=C2COP(O[Na])(O[Na])=O)C(S(=O)(O[Na])=O)=C1)(O[Na])=O
Molecular Formula
C14H10N3Na4O12PS2
Molecular Weight
599.30
Precautions
H315, H319, H335
References & Citations
[1]Flores-Soto E, et al. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674 (2-3) :439-44.|[2]Huo H, et al. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. J Biol Chem. 2018 Aug 17;293 (33) :12820-12831.|[3]Einfluss von ATP und seinen Derivaten auf die Aktivierung von Monozyten.|[4]Rost S, et al. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangialproliferative glomerulonephritis. Kidney Int. 2002 Nov;62 (5) :1659-71.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
P2X1 Receptor
Citation 01
BioRxiv. 2024 November 03.|Int Immunopharmacol. 2025 Sep 6:165:115494.|J Biol Chem. 2021 Oct;297 (4) :101166.|J Endocrinol Invest. 2025 Feb;48 (2) :317-332.|J Med Chem. 2025 May 8;68 (9) :9723-9740.|Mil Med Res. 2024 Jun 27;11 (1) :41.|Pharmacol Biochem Behav. 2025 Dec:257:174114.|ACS Chem Neurosci. 2025 Feb 5;16 (3) :374-383. |bioRxiv. 2023 Sep 17.

Related Products

CatalogName
HY-108960PPADS
HY-128036CDdATP (tetrasodium)
HY-139579APafolacianine (tetrasodium)
HY-19638A-01Cangrelor (tetrasodium)
HY-108675-01PPNDS (tetrasodium)
HY-137660APppApG (tetrasodium)
HY-139165A-01AT-9010 (tetrasodium)
HY-W127725Thymolphthalexon (tetrasodium)
HY-100168A-01BAPTA (tetrasodium)
HY-101308MRS2179 (tetrasodium)

Alternative Products

CatalogName
MBS5755402PPADS tetrasodium
256309-01PPADS tetrasodium salt
255529-01Iso-PPADS tetrasodium salt
sc-202770PPADS tetrasodium salt, anhydrous
T89112-01PPADS
MBS5758198Cangrelor tetrasodium
MBS5776868Denufosol tetrasodium
MBS5776996Eritoran Tetrasodium
T23018MRS2179 tetrasodium
T39095-01AT-9010 tetrasodium

Popular Products